News & Blog
News & Blog
FA Community Statement from Biogen
Press Release & Community Statement: PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich’s Ataxia
February 2025 – Advocacy Newsletter
Job Posting: Development Manager (Major Gifts)
Letter to the FA Community from Astellas Pharma
Webinar Recording: PTC Therapeutics Vatiquinone Program January 2025 Update
Janaury 2025 – Advocacy Newsletter
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Press Release & Community Letter: Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia